Skip to content

Earnings Screener Charts Portfolio Pricing

Connect your AI

Stocks
Avalo Therapeutics
Business Segments
Products & Services
Contingent consideration

Contingent consideration

Avalo Therapeutics·Products & Services·1 segment·Rolls up to Fair Value Measurement Disclosure

Breakdown

Segments

AVTX-007View metric

Explore

Earnings Calendar
Stock Screener
Metrics Screener
Charts
Watchlist
Portfolio

Resources

Pricing
Releases
About
Contact
Methodology
Cite & Reuse
Sign in / Sign up

Connect

Claude
Claude Code
ChatGPT
Codex
Codex CLI
Cursor
Other clients

Legal

Privacy Policy
Terms of Service
Cookie Policy
SEC EDGAR
support@opencapital.sh

© 2026 OpenCapital. All rights reserved.

Data sourced from SEC filings — methodology

OpenCapital is not affiliated with or endorsed by the U.S. Securities and Exchange Commission (SEC). All data is sourced from publicly available SEC filings.

Segment	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
AVTX-007	$8.5M	$8.1M	$10.7M	$23.2M	$18M	$17.5M
Total	$8.48M	$8.1M	—	—	$18M	$17.52M